{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Achieve Life Sciences, Inc. "},"Symbol":{"label":"Symbol","value":"ACHV"},"Address":{"label":"Address","value":"22722 29TH DRIVE SOUTHEAST SUITE 100, BOTHELL, British Columbia, WA 98021, Canada"},"Phone":{"label":"Phone","value":"+1 604 210-2217"},"Industry":{"label":"Industry","value":"Biotechnology: In Vitro &amp; In Vivo Diagnostic Substances"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline."},"CompanyUrl":{"label":"Company Url","value":"https://www.achievelifesciences.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Anthony John Clarke","title":"Chief Scientific Officer"},{"name":"Cindy A. Jacobs","title":"President, Chief Medical Officer &amp; Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}